Form 8-K X4 Pharmaceuticals, Inc For: Nov 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
X4 Pharmaceuticals (XFOR) PT Lowered to $4 at Stifel
November 13, 2024 4:00 PM ESTStifel analyst Stephen Willey lowered the price target on X4 Pharmaceuticals (NASDAQ: XFOR) to $4.00 (from $5.00) while maintaining a Buy rating.
The analyst comments "The XOLREMDI launch in WHIM syndrome was always going to be a show-me story for investors and the longer-term opportunity... More
